(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Xenetic Biosciences, Youngevity International, and Viveve Medical.

Rank Financial Asset Price Change Updated (EST)
1 Xenetic Biosciences (XBIOW) 1.00 66.65% 2022-04-11 23:49:12
2 Youngevity International (YGYIP) 6.00 15.16% 2022-04-12 01:15:12
3 Viveve Medical (VIVE) 1.18 10.28% 2022-04-11 19:11:05
4 Zynex (ZYXI) 6.53 7.4% 2022-04-12 03:47:13
5 VerifyMe (VRMEW) 1.02 6.46% 2022-04-11 19:49:12
6 Geo Group (GEO) 6.28 6.08% 2022-04-12 14:59:42
7 Summit Wireless Technologies (WISA) 1.23 4.24% 2022-04-11 22:44:13
8 Marathon Oil (MRO) 26.25 4.1% 2022-04-12 14:47:19
9 Freshpet (FRPT) 106.08 3.74% 2022-04-12 14:58:11
10 Devon Energy (DVN) 62.26 3.71% 2022-04-12 14:58:49

The three most active and biggest losers today are NASDAQ TEST STOCK, ViacomCBS, and Zosano Pharma Corporation.

Rank Financial Asset Price Change Updated (EST)
1 NASDAQ TEST STOCK (ZWZZT) 17.00 -45.16% 2022-04-12 03:23:11
2 ViacomCBS (VIAC) 29.58 -17.81% 2022-04-12 10:50:09
3 Zosano Pharma Corporation (ZSAN) 0.12 -17.67% 2022-04-12 03:13:05
4 Exicure (XCUR) 0.18 -14.08% 2022-04-12 01:06:05
5 Aspen Group (ASPU) 0.93 -10.58% 2022-04-12 14:50:22
6 Bilibili (BILI) 24.87 -9.8% 2022-04-12 14:54:14
7 CarMax (KMX) 93.29 -9.58% 2022-04-12 14:59:32
8 Castle Biosciences (CSTL) 28.05 -9.28% 2022-04-12 14:50:58
9 X4 Pharmaceuticals (XFOR) 1.60 -8.57% 2022-04-12 01:09:05
10 Liquid Media Group Ltd. (YVR) 0.72 -8.48% 2022-04-12 01:55:15

Most Active Winners today

1. Xenetic Biosciences (XBIOW) – 66.65%

NASDAQ ended the session with Xenetic Biosciences rising 66.65% to $1.00 on Tuesday, after five successive sessions in a row of losses. NASDAQ dropped 0.3% to $13,371.57, after two successive sessions in a row of losses, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Xenetic Biosciences is 6 which is 92.59% below its average volume of 81.

Xenetic Biosciences’s last close was $1.00, 82.08% under its 52-week high of $5.58.

Xenetic Biosciences’s Stock Yearly Top and Bottom Value

Xenetic Biosciences’s stock is valued at $1.00 at 17:32 EST, way below its 52-week high of $5.58 and way above its 52-week low of $0.50.

Xenetic Biosciences’s Moving Average

Xenetic Biosciences’s value is under its 50-day moving average of $1.04 and way below its 200-day moving average of $1.65.

More news about Xenetic Biosciences.

2. Youngevity International (YGYIP) – 15.16%

Youngevity International, Inc. is a distributor of health and nutrition products and services both in the United States as well internationally. The company operates three distinct segments, Direct Selling, Commercial Coffee and Commercial Hemp. It offers nutritional supplements and gourmet coffees as well as skincare and cosmetics. The company also makes and sells coffee products in the CafA (c) La Rica and CafA (c) Alma brands. It also markets a range of JavaFit coffees directly to customers under its Javalution Daily Grind and Javalution Urban Grind brands. It also offers hemp-derived cannabidiol oil. It sells equipment and coffee to retirement and wellness communities as well as various cruise lines, coffee service operators and distributors. Youngevity International, Inc. markets their products via a variety of websites, including youngevity.com, ygyi.com, heritagemakers.com, hempfx.com, clrroasters.com, cafelarica.com, javalution.com. The former name of the company was AL International, Inc., but it changed its name in July 2013 to Youngevity International, Inc. Youngevity International, Inc., was established in 1996. It is located in Chula Vista, California.

NASDAQ ended the session with Youngevity International rising 15.16% to $6.00 on Tuesday, following the last session’s upward trend. NASDAQ slid 0.3% to $13,371.57, after two successive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Volume

Today’s last reported volume for Youngevity International is 506 which is 432.63% above its average volume of 95.

Youngevity International’s last close was $6.00, 58.42% below its 52-week high of $14.43.

Youngevity International’s Revenue

Year-on-year quarterly revenue growth declined by 14.6%, now sitting on 147.44M for the twelve trailing months.

Youngevity International’s Stock Yearly Top and Bottom Value

Youngevity International’s stock is valued at $6.00 at 17:32 EST, way under its 52-week high of $14.43 and way higher than its 52-week low of $1.00.

Youngevity International’s Moving Average

Youngevity International’s worth is way above its 50-day moving average of $4.63 and under its 200-day moving average of $6.31.

More news about Youngevity International.

3. Viveve Medical (VIVE) – 10.28%

Viveve Medical, Inc. develops, produces, markets, and sells medical devices that can be used to treat various post-partum conditions. Viveve Systems, which is a radiofrequency generator and a single-use tip for treatment, are offered by the company. The company markets its products via distributors and sales staff in Canada, the United States and the Asia Pacific. Viveve Medical, Inc., was established in 2005. It is located in Englewood, Colorado.

NASDAQ ended the session with Viveve Medical jumping 10.28% to $1.18 on Tuesday while NASDAQ dropped 0.3% to $13,371.57.

Volume

Today’s last reported volume for Viveve Medical is 252367 which is 34.78% above its average volume of 187237.

Viveve Medical’s last close was $1.18, 63.69% below its 52-week high of $3.25.

Viveve Medical’s Sales

Viveve Medical’s sales growth is 11% for the ongoing quarter and 15.8% for the next. The company’s growth estimates for the ongoing quarter is 16.2% and a drop 30.6% for the next.

Viveve Medical’s Revenue

Year-on-year quarterly revenue growth declined by 12.4%, now sitting on 6.43M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Viveve Medical’s stock is considered to be oversold (<=20).

Viveve Medical’s Stock Yearly Top and Bottom Value

Viveve Medical’s stock is valued at $1.18 at 17:32 EST, way below its 52-week high of $3.25 and way higher than its 52-week low of $0.78.

Viveve Medical’s Moving Average

Viveve Medical’s worth is way higher than its 50-day moving average of $0.97 and way under its 200-day moving average of $1.79.

More news about Viveve Medical.

4. Zynex (ZYXI) – 7.4%

Zynex, Inc., via its subsidiaries, develops, manufactures, markets and sells medical devices for chronic and acute pain. It also activates and exercises muscles with electric stimulation to rehabilitate injured or disabled people. The company offers NexWave a multi-channel, dual-channel, multimodality interferencential current and transcutaneous electrical nerve stimulation, (TENS) and neuromuscular electric stimulation device. It also sells NeuroMove and InWave which are electromyography-triggered stimulation devices. It also distributes electrodes to deliver electrical current to the body as well as batteries for electrotherapy products. Comfortrac is available for cervical traction and JetStream hot/cold therapy. LSO Back Braces are for lumbar support. It also offers a blood volume monitor which is a medical device that measures central blood volume. This can be used in recovery and operating rooms for internal bleeding detection and blood loss. It offers products to help with pain control, stroke rehabilitation and recovery from spinal cord injuries. Zynex, Inc. sells products primarily through its direct sales force in the United States. It was established in 1996. The headquarters are located in Englewood in Colorado.

NASDAQ ended the session with Zynex jumping 7.4% to $6.53 on Tuesday while NASDAQ dropped 0.3% to $13,371.57.

Volume

Today’s last reported volume for Zynex is 686487 which is 74.8% above its average volume of 392708.

Zynex’s last close was $6.53, 59.84% under its 52-week high of $16.26.

Zynex’s Sales

Zynex’s sales growth is 61.5% for the current quarter and 54.3% for the next. The company’s growth estimates for the present quarter and the next is 280% and 450%, respectively.

Zynex’s Revenue

Year-on-year quarterly revenue growth grew by 57.6%, now sitting on 130.3M for the twelve trailing months.

Zynex’s Stock Yearly Top and Bottom Value

Zynex’s stock is valued at $6.53 at 17:32 EST, way below its 52-week high of $16.26 and way higher than its 52-week low of $4.97.

Zynex’s Moving Average

Zynex’s worth is higher than its 50-day moving average of $6.38 and way below its 200-day moving average of $10.27.

More news about Zynex.

5. VerifyMe (VRMEW) – 6.46%

NASDAQ ended the session with VerifyMe rising 6.46% to $1.02 on Tuesday while NASDAQ dropped 0.3% to $13,371.57.

VerifyMe’s last close was $1.02, 4.2% higher than its 52-week high of $0.98.

VerifyMe’s Stock Yearly Top and Bottom Value

VerifyMe’s stock is valued at $1.02 at 17:32 EST, above its 52-week high of $0.98.

More news about VerifyMe.

6. Geo Group (GEO) – 6.08%

GEO Group (NYSE : GEO) was the first equity real estate trust that is fully integrated. It specializes in secure facilities, community reentry centres, as well as the financing, development and management of processing centers and other security-related infrastructures in the United States. GEO provides community-based services, including post-release support and electronic monitoring as well as enhanced in-custody rehabilitation. GEO has approximately 93,000 beds in 125 facilities worldwide. There are also projects underway. The company employs approximately 23,000 people.

NYSE ended the session with Geo Group rising 6.08% to $6.28 on Tuesday while NYSE dropped 0.41% to $16,465.99.

Volume

Today’s last reported volume for Geo Group is 1643700 which is 40.38% below its average volume of 2757160.

Geo Group’s last close was $5.53, 49.73% under its 52-week high of $11.00.

Geo Group’s Sales

Geo Group’s sales growth is a negative 3.5% for the ongoing quarter and a decline by 6.1% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 154.5% and a negative 17.9%, respectively.

Geo Group’s Revenue

Year-on-year quarterly revenue growth declined by 3.8%, now sitting on 2.28B for the twelve trailing months.

Geo Group’s Stock Yearly Top and Bottom Value

Geo Group’s stock is valued at $6.28 at 17:32 EST, way below its 52-week high of $11.00 and way higher than its 52-week low of $4.96.

Geo Group’s Moving Average

Geo Group’s worth is under its 50-day moving average of $6.37 and way below its 200-day moving average of $7.39.

More news about Geo Group.

7. Summit Wireless Technologies (WISA) – 4.24%

Summit Wireless Technologies, Inc. designs and manufactures integrated wireless circuits for professional and home audio markets throughout the United States, Europe, Asia Pacific, and Asia. The company offers TX modules that can be integrated into TVs, audio-visual receivers and media hubs as well as USB and HDMI dongles and speaker systems. It sells products direct to original equipment makers. Summit Semiconductor, Inc. was the company’s former name. In September 2018, Summit Wireless Technologies, Inc. became its new name. Summit Semiconductor, Inc. is an American company that was established in San Jose, California in 2010.

NASDAQ ended the session with Summit Wireless Technologies rising 4.24% to $1.23 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.3% to $13,371.57, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for Summit Wireless Technologies is 74472 which is 49.78% below its average volume of 148295.

Summit Wireless Technologies’s last close was $1.23, 82.58% under its 52-week high of $7.06.

Summit Wireless Technologies’s Sales

Summit Wireless Technologies’s sales growth is 82.1% for the ongoing quarter and 37.3% for the next. The company’s growth estimates for the ongoing quarter and the next is 31.2% and 48.5%, respectively.

Summit Wireless Technologies’s Revenue

Year-on-year quarterly revenue growth grew by 197.7%, now sitting on 5.58M for the twelve trailing months.

Summit Wireless Technologies’s Stock Yearly Top and Bottom Value

Summit Wireless Technologies’s stock is valued at $1.23 at 17:32 EST, way below its 52-week high of $7.06 and way above its 52-week low of $1.00.

Summit Wireless Technologies’s Moving Average

Summit Wireless Technologies’s worth is under its 50-day moving average of $1.23 and way under its 200-day moving average of $2.28.

More news about Summit Wireless Technologies.

8. Marathon Oil (MRO) – 4.1%

Marathon Oil Corporation is an independent exploration company in Equatorial Guinea and the United States. It is involved in exploration, production, marketing, and distribution of crude oil, condensate and natural gas liquids; as well as the marketing and production of natural gas products such as liquefied natural gases and methanol. The company also owns 32 central gathering facilities, the Sugarloaf gathering network, a 42-mile natural gaz pipeline that runs through Karnes County and Atascosa Counties. It had proved developed reserves of 721 million barrels (mmboe) and 484 mmboe as of December 31, 2019. The former name of the company was USX Corporation. In July 2001, it changed its name from Marathon Oil Corporation to Marathon Oil Corporation. Marathon Oil Corporation was established in 1887. It is located in Houston, Texas.

NYSE ended the session with Marathon Oil jumping 4.1% to $26.25 on Tuesday, after two sequential sessions in a row of losses. NYSE fell 0.41% to $16,465.99, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Marathon Oil is 19396000 which is 11.87% below its average volume of 22010700.

Marathon Oil’s last close was $23.17, 12.23% below its 52-week high of $26.40.

Marathon Oil’s Sales

Marathon Oil’s sales growth is 86% for the present quarter and 43.9% for the next. The company’s growth estimates for the current quarter and the next is 550% and 176.2%, respectively.

Marathon Oil’s Revenue

Year-on-year quarterly revenue growth grew by 88.4%, now sitting on 4.71B for the twelve trailing months.

Marathon Oil’s Stock Yearly Top and Bottom Value

Marathon Oil’s stock is valued at $26.25 at 17:32 EST, under its 52-week high of $26.40 and way higher than its 52-week low of $9.70.

Marathon Oil’s Moving Average

Marathon Oil’s value is way above its 50-day moving average of $22.98 and way higher than its 200-day moving average of $16.69.

More news about Marathon Oil.

9. Freshpet (FRPT) – 3.74%

Freshpet, Inc. produces and markets fresh, natural products, frozen meals, treats, and other pet care items in the United States, Canada, the United Kingdom, and internationally. It sells products under its Freshpet and Dognation brands. The brand is also available online. Freshpet, Inc., was established in Secaucus, New Jersey in 2004.

NASDAQ ended the session with Freshpet jumping 3.74% to $106.08 on Tuesday, following the last session’s downward trend. NASDAQ slid 0.3% to $13,371.57, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Freshpet is 524472 which is 8.97% above its average volume of 481262.

Freshpet’s last close was $102.26, 45.31% under its 52-week high of $186.98.

Freshpet’s Sales

Freshpet’s sales growth is 44.6% for the ongoing quarter and 36.7% for the next. The company’s growth estimates for the current quarter is a negative 25% and positive 19.2% for the next.

Freshpet’s Revenue

Year-on-year quarterly revenue growth grew by 27.8%, now sitting on 394.14M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Freshpet’s stock is considered to be overbought (>=80).

Freshpet’s Stock Yearly Top and Bottom Value

Freshpet’s stock is valued at $106.08 at 17:32 EST, way below its 52-week high of $186.98 and way higher than its 52-week low of $78.81.

Freshpet’s Moving Average

Freshpet’s value is above its 50-day moving average of $96.95 and way under its 200-day moving average of $121.13.

More news about Freshpet.

10. Devon Energy (DVN) – 3.71%

Devon Energy Corporation is an independent energy company that specializes in exploration, development and production of natural gas and natural gas liquids. The company has approximately 3955 gross wells. It was established in 1971. The headquarters are located in Oklahoma City, Oklahoma.

NYSE ended the session with Devon Energy jumping 3.71% to $62.26 on Tuesday while NYSE fell 0.41% to $16,465.99.

Volume

Today’s last reported volume for Devon Energy is 8500580 which is 37.47% below its average volume of 13594600.

Devon Energy’s last close was $58.64, 7.3% below its 52-week high of $63.26.

Devon Energy’s Sales

Devon Energy’s sales growth is 193.6% for the ongoing quarter and 110.6% for the next.

Devon Energy’s Revenue

Year-on-year quarterly revenue growth grew by 214.1%, now sitting on 10.41B for the twelve trailing months.

Devon Energy’s Stock Yearly Top and Bottom Value

Devon Energy’s stock is valued at $62.26 at 17:32 EST, under its 52-week high of $63.26 and way higher than its 52-week low of $20.14.

Devon Energy’s Moving Average

Devon Energy’s value is above its 50-day moving average of $56.68 and way above its 200-day moving average of $41.54.

More news about Devon Energy.

Most Active Losers Today

1. NASDAQ TEST STOCK (ZWZZT) – -45.16%

NASDAQ ended the session with NASDAQ TEST STOCK falling 45.16% to $17.00 on Tuesday while NASDAQ slid 0.3% to $13,371.57.

NASDAQ TEST STOCK’s last close was $26.00, 52.94% above its 52-week high of $17.00.

NASDAQ TEST STOCK’s Stock Yearly Top and Bottom Value

NASDAQ TEST STOCK’s stock is valued at $17.00 at 17:32 EST, under its 52-week low of $17.00.

More news about NASDAQ TEST STOCK.

2. ViacomCBS (VIAC) – -17.81%

NASDAQ ended the session with ViacomCBS falling 17.81% to $29.58 on Tuesday, after three consecutive sessions in a row of losses. NASDAQ dropped 0.3% to $13,371.57, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for ViacomCBS is 87514000 which is 461.24% above its average volume of 15592900.

ViacomCBS’s last close was $35.91, 64.78% under its 52-week high of $101.97.

The company’s growth estimates for the current quarter and the next is a negative 16.5% and a negative 30.8%, respectively.

ViacomCBS’s Revenue

Year-on-year quarterly revenue growth grew by 13.2%, now sitting on 27.46B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

ViacomCBS’s stock is considered to be oversold (<=20).

ViacomCBS’s Stock Yearly Top and Bottom Value

ViacomCBS’s stock is valued at $29.58 at 17:32 EST, way under its 52-week high of $101.97 and above its 52-week low of $28.90.

ViacomCBS’s Moving Average

ViacomCBS’s value is way below its 50-day moving average of $35.62 and way below its 200-day moving average of $43.11.

More news about ViacomCBS.

3. Zosano Pharma Corporation (ZSAN) – -17.67%

Zosano Pharma Corporation is a biopharmaceutical company in clinical stages. It specializes in providing migraine therapy to sufferers using the Adhesive Dermally Applied Microarray technology. Qtrypta, a unique formulation of zolmitriptan that is used to treat migraines (M207), is the company’s leading product candidate. Fremont is the headquarters of this company, which was established in 2006.

NASDAQ ended the session with Zosano Pharma Corporation falling 17.67% to $0.12 on Tuesday while NASDAQ dropped 0.3% to $13,371.57.

Volume

Today’s last reported volume for Zosano Pharma Corporation is 18399100 which is 18% above its average volume of 15591400.

Zosano Pharma Corporation’s last close was $0.12, 89.47% below its 52-week high of $1.14.

The company’s growth estimates for the present quarter and the next is 37.5% and 33.3%, respectively.

Zosano Pharma Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 61.2%, now sitting on 785k for the twelve trailing months.

Zosano Pharma Corporation’s Stock Yearly Top and Bottom Value

Zosano Pharma Corporation’s stock is valued at $0.12 at 17:32 EST, way under its 52-week high of $1.14 and higher than its 52-week low of $0.11.

Zosano Pharma Corporation’s Moving Average

Zosano Pharma Corporation’s value is way below its 50-day moving average of $0.23 and way under its 200-day moving average of $0.55.

More news about Zosano Pharma Corporation.

4. Exicure (XCUR) – -14.08%

Exicure, Inc. is a biotechnology company in clinical stage. It develops therapies for neurology, immunooncology, and inflammatory disorders using its proprietary Spherical Nucleic Acid (SNA). Its drug candidate, AST-008, is currently in Phase 1b/2 clinical trials with patients with advanced solid tumours. The company also has XCURFXN (a SNAA-based therapeutic agent) in preclinical studies for Friedreich’s Ataxia. XCUR17 is an SNA which targets messenger RNA (mRNA), which encodes interleukin-17 receptor alpha. The company has an option, collaboration, and license agreement for SNA-based treatment for hair loss disorders with Allergan Pharmaceuticals International Limited. It also has a license and development agreement for DERMELIX, LLC, to help develop, commercialize, and research its technology to treat netherton syndrome. It was established in Chicago, Illinois in 2011.

NASDAQ ended the session with Exicure dropping 14.08% to $0.18 on Tuesday, following the last session’s downward trend. NASDAQ slid 0.3% to $13,371.57, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Exicure is 16432100 which is 14.97% above its average volume of 14292400.

Exicure’s last close was $0.18, 91.03% under its 52-week high of $2.03.

The company’s growth estimates for the current quarter and the next is 50% and 75%, respectively.

Exicure’s Revenue

Year-on-year quarterly revenue growth grew by 1412.9%, now sitting on -483k for the twelve trailing months.

Exicure’s Stock Yearly Top and Bottom Value

Exicure’s stock is valued at $0.18 at 17:33 EST, way under its 52-week high of $2.03 and way above its 52-week low of $0.14.

Exicure’s Moving Average

Exicure’s worth is way below its 50-day moving average of $0.21 and way under its 200-day moving average of $0.78.

More news about Exicure.

5. Aspen Group (ASPU) – -10.58%

Aspen Group, Inc., a technology-based education company, offers online higher education in the United States. It offers certificates, associate, bachelor, master’s and doctoral degrees in many areas including business, technology and nursing. It had 11444 students who were pursuing degrees as of April 30, 2020. It was established in New York in 1987.

NASDAQ ended the session with Aspen Group sliding 10.58% to $0.93 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ fell 0.3% to $13,371.57, after two successive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Aspen Group is 170354 which is 32.33% below its average volume of 251762.

Aspen Group’s last close was $1.01, 86.48% under its 52-week high of $7.49.

Aspen Group’s Revenue

Year-on-year quarterly revenue growth grew by 11.6%, now sitting on 74.05M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Aspen Group’s stock is considered to be overbought (>=80).

Aspen Group’s Stock Yearly Top and Bottom Value

Aspen Group’s stock is valued at $0.93 at 17:33 EST, way below its 52-week high of $7.49 and above its 52-week low of $0.90.

Aspen Group’s Moving Average

Aspen Group’s worth is way below its 50-day moving average of $1.51 and way below its 200-day moving average of $4.08.

More news about Aspen Group.

6. Bilibili (BILI) – -9.8%

Bilibili Inc. offers online entertainment for young people in China’s People’s Republic of China. The platform provides a variety of content including mobile games and video services as well as value-added and ACG-related audio and comic content. It offers video services that include occupationally-generated videos and professional user videos. Bilibili Inc. was established in Shanghai, People’s Republic of China in 2009.

NASDAQ ended the session with Bilibili falling 9.8% to $24.87 on Tuesday while NASDAQ fell 0.3% to $13,371.57.

Volume

Today’s last reported volume for Bilibili is 12135200 which is 13.3% above its average volume of 10710500.

Bilibili’s last close was $19.02, 85.28% below its 52-week high of $129.24.

Bilibili’s Sales

Bilibili’s sales growth is 52.2% for the present quarter and 52.7% for the next. The company’s growth estimates for the present quarter and the next is a negative 120.7% and a negative 55.2%, respectively.

Bilibili’s Revenue

Year-on-year quarterly revenue growth grew by 61.4%, now sitting on 17.44B for the twelve trailing months.

Bilibili’s Stock Yearly Top and Bottom Value

Bilibili’s stock is valued at $24.87 at 17:33 EST, way below its 52-week high of $129.24 and way above its 52-week low of $14.93.

Bilibili’s Moving Average

Bilibili’s value is way below its 50-day moving average of $29.69 and way under its 200-day moving average of $62.10.

More news about Bilibili.

7. CarMax (KMX) – -9.58%

CarMax, Inc., via its subsidiaries, is a dealer of used cars in the United States. CarMax Sales Operations is one segment, while CarMax Auto Finance is another. Customers can choose from a variety of make and model used cars, such as domestic and imported luxury and import vehicles. Vehicles that don’t meet the company’s retail standards are sold to licensed dealers via on-site wholesale auctions. Extended protection plans for customers are also available at time of sale. It also offers vehicle repair and reconditioning services. The CarMax Auto Finance program and other arrangements with financial institutions provides financing options for retailers. It had approximately 221 stores as well as two new franchises. CarMax, Inc., was established in 1993 in Richmond, Virginia.

NYSE ended the session with CarMax falling 9.58% to $93.29 on Tuesday while NYSE dropped 0.41% to $16,465.99.

Volume

Today’s last reported volume for CarMax is 8043550 which is 391.52% above its average volume of 1636450.

CarMax’s last close was $99.21, 36.4% under its 52-week high of $155.98.

News about CarMax today

  • Carmax says used-car sales hit by waning consumer confidence. According to today’s article on Bloomberg Quint, "The average price of a car rose 40%, or $8,300, in the period ended Feb. 28 compared with a year ago, CarMax said in a statement Tuesday."

The company’s growth estimates for the current quarter is 12.6% and a drop 17.9% for the next.

CarMax’s Revenue

Year-on-year quarterly revenue growth grew by 61.8%, now sitting on 30.63B for the twelve trailing months.

CarMax’s Stock Yearly Top and Bottom Value

CarMax’s stock is valued at $93.29 at 17:33 EST, below its 52-week low of $94.35.

CarMax’s Moving Average

CarMax’s worth is way under its 50-day moving average of $104.05 and way under its 200-day moving average of $126.32.

More news about CarMax.

8. Castle Biosciences (CSTL) – -9.28%

Castle Biosciences, Inc., which is a company that develops and markets diagnostic and prognostic tools for skin cancers, has reached commercial stage. DecisionDx–Melanoma is the company’s flagship product. This multi-gene expression profil (GEP test) identifies stage I/I patients who are at highest risk for metastasis using biological information from 31 tumor tissues. DecisionDx-UM is a GEP proprietary test which predicts metastasis risk for patients suffering from uveal melanoma. There are also two proprietary products at late stage that address cutaneous squamous cells carcinoma and suspicious pigmented lesion, both indications of high clinical need in dermatological. The company offers testing services via physicians, nurse practitioners, and physician assistants. It was established in Texas in 2007.

NASDAQ ended the session with Castle Biosciences falling 9.28% to $28.05 on Tuesday while NASDAQ slid 0.3% to $13,371.57.

Volume

Today’s last reported volume for Castle Biosciences is 659797 which is 196.17% above its average volume of 222772.

Castle Biosciences’s last close was $30.92, 60.82% under its 52-week high of $78.92.

Castle Biosciences’s Sales

Castle Biosciences’s sales growth is 35% for the present quarter and 48.8% for the next. The company’s growth estimates for the current quarter and the next is a negative 113% and a negative 200%, respectively.

Castle Biosciences’s Revenue

Year-on-year quarterly revenue growth grew by 44.7%, now sitting on 94.08M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Castle Biosciences’s stock is considered to be overbought (>=80).

Castle Biosciences’s Stock Yearly Top and Bottom Value

Castle Biosciences’s stock is valued at $28.05 at 17:33 EST, way below its 52-week low of $31.46.

Castle Biosciences’s Moving Average

Castle Biosciences’s worth is way under its 50-day moving average of $42.36 and way below its 200-day moving average of $54.71.

More news about Castle Biosciences.

9. X4 Pharmaceuticals (XFOR) – -8.57%

X4 Pharmaceuticals, Inc. is a biopharmaceutical company in clinical stage. It focuses on developing, commercializing, and distributing novel therapies for primary immuno-deficiencies, as well as cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and WaldenstrAPm macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. Additionally, X4P002 is being developed for the treatment glioblastoma multifle; and X4P003 to treat primary immuno-deficiencies. Abbisko Therapeutics Co. Ltd. has granted it a license to manufacture and market mavorixafor, in conjunction with other checkpoint inhibitors, or agents for oncology indications. Arsanis, Inc. was the company’s former name. In March 2019, X4 Pharmaceuticals, Inc. became X4 Pharmaceuticals, Inc. X4 Pharmaceuticals, Inc. is a Massachusetts-based company that was established in 2014.

NASDAQ ended the session with X4 Pharmaceuticals falling 8.57% to $1.60 on Tuesday while NASDAQ dropped 0.3% to $13,371.57.

Volume

Today’s last reported volume for X4 Pharmaceuticals is 296444 which is 30.71% below its average volume of 427876.

X4 Pharmaceuticals’s last close was $1.60, 83.84% below its 52-week high of $9.90.

The company’s growth estimates for the current quarter and the next is 53.1% and 17.6%, respectively.

X4 Pharmaceuticals’s Stock Yearly Top and Bottom Value

X4 Pharmaceuticals’s stock is valued at $1.60 at 17:33 EST, way below its 52-week high of $9.90 and way higher than its 52-week low of $1.31.

X4 Pharmaceuticals’s Moving Average

X4 Pharmaceuticals’s value is way below its 50-day moving average of $1.84 and way below its 200-day moving average of $3.89.

More news about X4 Pharmaceuticals.

10. Liquid Media Group Ltd. (YVR) – -8.48%

Liquid Media Group Ltd. is a media- and entertainment company. It offers videogame products for casual gamers and also publishes games on interactive entertainment platforms. The company also provides production and gaming services, as well as visual effects and video games. It distributes TV and film content via its digital platforms. Liquid Media Group Ltd. has its headquarters in Vancouver, Canada.

NASDAQ ended the session with Liquid Media Group Ltd. sliding 8.48% to $0.72 on Tuesday, after five successive sessions in a row of losses. NASDAQ dropped 0.3% to $13,371.57, after two consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for Liquid Media Group Ltd. is 491171 which is 22.43% below its average volume of 633267.

Liquid Media Group Ltd.’s last close was $0.72, 77.29% below its 52-week high of $3.17.

Liquid Media Group Ltd.’s Revenue

Year-on-year quarterly revenue growth declined by 1.1%, now sitting on 45.09k for the twelve trailing months.

Liquid Media Group Ltd.’s Stock Yearly Top and Bottom Value

Liquid Media Group Ltd.’s stock is valued at $0.72 at 17:33 EST, way below its 52-week high of $3.17 and way above its 52-week low of $0.54.

Liquid Media Group Ltd.’s Moving Average

Liquid Media Group Ltd.’s worth is above its 50-day moving average of $0.72 and way under its 200-day moving average of $1.30.

More news about Liquid Media Group Ltd..

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here